Filing Flows › Edwards Lifesciences (EW) › Guidance & outlook
Edwards Lifesciences (EW) guidance and outlook
Edwards Lifesciences (EW) raised its guidance on Nov 4, 2026: Revenue +11.5% for FY2026; EPS $2.97–$3.05 for FY2026; EPS +18% for FY2026; Gross margin 78%–79% for FY2026. Edwards Lifesciences' 10-Q filed Nov 4, 2026 makes 10 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | +11.5% | raised |
| Revenue | FY2026 | +9% to +9.5% | raised |
| Revenue | FY2026 | $780M–$790M | raised |
| EPS | FY2026 | $2.97–$3.05 | raised |
| EPS | FY2026 | +18% | raised |
| Gross margin | FY2026 | 78%–79% | reaffirmed |
| Tax rate | FY2026 | 16%–19% | reaffirmed |
| Revenue | Q3 2026 | +9% to +9.5% | raised |
| Revenue | FY2026 | $780M–$790M | raised |
| Revenue | Q4 2026 | $1.7B–$1.8B | new |
| EPS | Q4 2026 | $0.61–$0.69 | new |
From the earnings release filed Nov 4, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 4, 2026
- Due to changes to U.S. trade policy, such as increased tariffs on imports and including non-U.S. retaliatory tariffs, we have and will continue to assess potential impacts on our business.
- As needed, we will pursue options to mitigate the impact of tariffs, including through our supply chain and potential exemptions and exclusions.
- Given the uncertainties around U.S. trade policy and future tariff rates, we are unable to predict the nature of the tariffs and whether we will be able to successfully mitigate their impact.
- As a result of the change in California law noted above, we have concluded that in applying our methodology where newly generated credits are utilized before existing carryforwards, the annual utilization limit will be lower than the newly generated research and development tax credits and excess research and development credits will continue to be generated annually on a prospective basis.
- Safe Harbour through the course of 2026, we will evaluate the potential effects of Pillar Two on our effective tax rate.
- In 2026, we expect the Pillar Two provisions to result in additional tax expense of approximately $45.0 million prior to offsets under current law.
- We plan to vigorously contest the additional tax claimed by the IRS through the judicial process.
- We intend to pursue all available remedies with respect to any unagreed issues, including administrative appeals and, if necessary, litigation, a process that could extend over several years.
- If necessary, we expect to defend that position through judicial proceedings.
- We consider several factors in determining when to execute share repurchases, including, among other things, expected dilution from stock plans, cash capacity, and the market price of our common stock.
Edwards Lifesciences' latest quarter
Edwards Lifesciences, Q3 2026: revenue $1.7B (+10% year over year), operating margin 17.4%, net earnings $308M, operating cash flow $570M. The chart follows the revenue to costs, profit and cash.
Questions
Did Edwards Lifesciences raise or lower its guidance?
Edwards Lifesciences (EW) raised its guidance on Nov 4, 2026: Revenue +11.5% for FY2026; EPS $2.97–$3.05 for FY2026; EPS +18% for FY2026; Gross margin 78%–79% for FY2026.
What does Edwards Lifesciences expect?
Due to changes to U.S. trade policy, such as increased tariffs on imports and including non-U.S. retaliatory tariffs, we have and will continue to assess potential impacts on our business. As needed, we will pursue options to mitigate the impact of tariffs, including through our supply chain and potential exemptions and exclusions. Given the uncertainties around U.S. trade policy and future tariff rates, we are unable to predict the nature of the tariffs and whether we will be able to successfully mitigate their impact.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.